Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$1.79B+70.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vincent C. Tizzio
- Sector
- Financial Services
- Industry
- Insurance - Diversified
- Employees
- 1,966
- Beta
- 0.46
- Country
- BM
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.97
Financials
Revenue
$1.79B+70.3%Net Income
$209.08M+40.4%EBITDA
$278.51M+66.6%Free Cash Flow
$866.18M+596.9%EPS (diluted)
$2.75+85.8%Shares Outstanding (diluted)
73.37M-17.1%Operating Expenses
$538.87MCash & Debt
$15.90BReturn of Capital
$149.30MRevenue by Segment (annual)
$5.71BDividend per Share
$0.44Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.56B | $1.01B | $12.52 |
| 2024 | $6.02B | $1.08B | $12.49 |
| 2023 | $5.59B | $376.29M | $4.06 |
| 2022 | $5.30B | $223.08M | $2.27 |
| 2021 | $5.32B | $618.61M | $6.95 |
| 2020 | $4.76B | $-120.42M | $-1.79 |
| 2019 | $5.19B | $323.47M | $3.37 |
| 2018 | $5.12B | $43.02M | $0.52 |
| 2017 | $4.44B | $-368.97M | $-4.39 |
| 2016 | $4.13B | $513.37M | $5.13 |
| 2015 | $4.23B | $641.63M | $6.10 |
| 2014 | $4.45B | $810.75M | $7.38 |
| 2013 | $4.17B | $727.47M | $6.02 |
| 2012 | $3.90B | $547.24M | $4.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AXS's reported EPS growth of 9.1% a year over 13 years.
- EPS in 5 years
- $19.94
- Implied price
- $179.49
- Return from $106.40
- 11.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $89.24 — -16.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -0.9% | -10.3% | -4.1% | 0.8% | 5.0% | 8.5% |
| 4.1% | -5.8% | 0.7% | 5.9% | 10.3% | 14.0% |
| 9.1% | -1.3% | 5.6% | 11.0% | 15.6% | 19.5% |
| 14.1% | 3.2% | 10.4% | 16.1% | 20.9% | 25.0% |
| 19.1% | 7.8% | 15.3% | 21.2% | 26.2% | 30.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (12)
- Newsdefenseworld.net·1d ago·Negative
Axis Capital Holdings Limited $AXS Shares Sold by Boston Partners Boston Partners cut its stake in shares of Axis Capital Holdings Limited (NYSE: AXS) by 6.3% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,679 shares of the insurance provider's stock after selling 27,490 shares during the
View source ↗ - Newsseekingalpha.com·24d ago·Positive
AXIS Capital Holdings Limited (AXS) Q3 2026 Earnings Call Transcript AXIS Capital Holdings Limited ( AXS ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Clifford Gallant - Head of Investor Relations & Corporate Development Vincent Tizzio - President, CEO & Director Matthew Kirk - Chief Financial Officer Conference Call Participants Christopher Golden - Mizuho Securities USA LLC, Research Division Charles Lederer - BMO Capital Markets Equity Research Andrew Kligerman - T…
View source ↗ - Newszacks.com·25d ago·Neutral
Here's What Key Metrics Tell Us About Axis Capital (AXS) Q3 Earnings The headline numbers for Axis Capital (AXS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·25d ago·Positive
Axis Capital (AXS) Tops Q3 Earnings and Revenue Estimates Axis Capital (AXS) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.97 per share. This compares to earnings of $3.25 per share a year ago.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…to $73.69 at September 30, 2025 PEMBROKE, Bermuda, Oct. 28, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or "the Company") (NYSE: AXS) today announced financial results for the third quarter ended September 30, 2026. Commenting on the third quarter 2026 financial results, Vince Tizzio, President and CEO of AXIS Capital said: "This was a strong quarter for AXIS, as our team leaned into attractive underwriting opportunities while practicing disciplined cycle man…
View source ↗ - Newsprnewswire.com·37d ago·Neutral
BCRF Launches $100 Million Venture Program for Breast Cancer: NYSE Content Update NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Oct. 16, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
View source ↗ - Newszacks.com·51d ago·Neutral
AXIS Capital's Specialty Focus Supports Growth and Shareholder Returns AXS' specialty focus, disciplined underwriting and rising investment yields support growth, while catastrophe and geopolitical risks remain key considerations.
View source ↗ - Newsbusinesswire.com·59d ago·Neutral
AXS and Denver Arts & Venues Launch Beyond AXS Community Initiative in Denver DENVER--(BUSINESS WIRE)--AXS and Denver Arts & Venues Launch Beyond AXS Community Initiative in Denver.
View source ↗ - Newszacks.com·82d ago·Neutral
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active…
View source ↗ - Newsseekingalpha.com·100d ago·Neutral
AXS PFD E Offers Competitive Yield Versus Other Insurance Companies AXIS Capital Holdings Limited offers diversified specialty insurance and reinsurance, with strong A+ credit ratings and a BBB-rated preferred stock AXS.PR.E. AXS reported 15% YOY growth in both premiums written and diluted book value, with a solid 93.1% combined ratio, though reinsurance premiums declined 25%. The fixed-rate, non-cumulative Series E preferred AXS.PR.E offers QDI-eligible dividends and BBB credit quality, appeali…
View source ↗ - Newszacks.com·102d ago·Negative
AXS Lags Industry, Trades at a Discount: Here's How to Play the Stock AXIS Capital's specialty focus, premium growth and capital returns support growth, while catastrophe losses and competition pressure on underwriting margins.
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $3.00 per share
Typical surprise +9.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$3.12 vs $2.85beat
- Tue, Jul 28$2.84 vs $3.25miss
- Wed, Apr 29$3.42 vs $3.33beat
- Wed, Jan 28$3.25 vs $2.97beat
- Wed, Oct 29$3.25 vs $2.72beat
- Tue, Jul 29$3.29 vs $2.88beat
Estimates and results for AXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AXS officers and directors.
- Bought
- $854k
- Sold
- $640.3m
4 trades
10 trades
- Smith Henry Bsold
- Smith Henry Bsold
- Davis Charles Asold
- Smith Henry Bsold
- Draper Daniel Jsold
- Draper Daniel Jsold
- Draper Daniel Jsold
- Davis Charles Asold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 2, 2023 (22d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 3, 2022 (16d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Jul 6, 2021 (32d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (312d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Aug 4, 2020 (26d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
